Arvinas (ARVN) Stock Forecast, Price & News

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.

16 brokers have issued 12-month price targets for Arvinas' stock. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they anticipate the company's stock price to reach $67.33 in the next twelve months. This suggests a possible upside of 174.8% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.

Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN stock has decreased by 28.4% and is now trading at $24.50.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ARVN earnings forecast.

Arvinas, Inc. (NASDAQ:ARVN) announced its quarterly earnings data on Friday, May, 5th. The company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by $0.05. The business earned $32.50 million during the quarter, compared to analysts' expectations of $27.74 million. Arvinas had a negative trailing twelve-month return on equity of 50.85% and a negative net margin of 227.86%. Arvinas's revenue for the quarter was up 22.6% on a year-over-year basis. During the same quarter last year, the company earned ($1.20) EPS.

ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares U.S. Pharmaceuticals ETF (IHE), Harbor Disruptive Innovation ETF (INNO), Principal Healthcare Innovators ETF (BTEC) and BlackRock Future Health ETF (BMED).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (10.71%), BlackRock Inc. (8.38%), EcoR1 Capital LLC (6.96%), Price T Rowe Associates Inc. MD (4.71%), ArrowMark Colorado Holdings LLC (2.94%) and State Street Corp (2.07%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $24.50.

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.31 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.66) on an earnings per share basis.

The company employs 280 workers across the globe.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.